Shopping Cart 0
Cart Subtotal
USD 0

Abeona Therapeutics Inc (ABEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. The company's lead programs include ABO-101 and ABO-102 adeno-associated virus. Abeona is also develops EB-101 for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 for rare blood diseases. The company has partnership with for the commercialization of its products in the US, European Union, Switzerland, Norway, Iceland, Lichtenstein, Australia, New Zealand, China and South Korea. Abeona is headquartered in Dallas, Texas, the US.

Abeona Therapeutics Inc (ABEO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 15

Venture Financing 15

Abeona Therapeutics Raises USD3.6 Million in Venture Financing 15

Abeona Therapeutics Raises USD 0.75 Million In Seed Financing 16

Partnerships 17

Abeona Therapeutics Partners with EB Research Partnership and EB Medical Research Foundation 17

Abeona Therapeutics Enters into Partnership Agreement with University of Nebraska Medical Center 18

Licensing Agreements 19

Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 19

Abeona Therapeutics Enters into Licensing Agreement with University of North Carolina at Chapel Hill 20

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 21

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 22

PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 23

PlasmaTech Biopharma Enters into Licensing Agreement with UNeMed 24

Access Pharma Enters into Licensing Agreement with Plasma Technologies 25

PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 26

Access Pharma Enters into Licensing Agreement with Norgine for MuGard 27

Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 28

Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 29

Equity Offering 30

Abeona Therapeutics Plans to Raise USD500 Million in Public Offering of Securities 30

Abeona Therapeutics Raises USD92 Million in Public Offering of Shares 31

Abeona Therapeutics Raises USD44 Million in Public Offering of Shares 33

Abeona Therapeutics Raises USD42 Million in Public Offering of Shares 35

Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 37

Abeona Therapeutics Raises USD4.6 Million in Private Placement of Shares up on Exercise of Warrants 38

PlasmaTech Biopharma Raises USD10 Million in Private Placement of Shares 39

PlasmaTech Biopharma Raises USD7 Million in Private Placement of Shares 40

PlasmaTech Biopharma Raises USD14 Million in Public Offering of Shares and Warrants 41

Access Pharma Completes Private Placement Of Units For USD 4.7 Million 43

Access Pharma Files Registration Statement For Public Offering Of Units 44

Acquisition 45

PlasmaTech Biopharma Acquires Abeona Therapeutics 45

Abeona Therapeutics Inc-Key Competitors 46

Abeona Therapeutics Inc-Key Employees 47

Abeona Therapeutics Inc-Locations And Subsidiaries 48

Head Office 48

Other Locations & Subsidiaries 48

Recent Developments 49

Strategy And Business Planning 49

Oct 04, 2017: Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio 49

Financial Announcements 50

Aug 09, 2018: Abeona Therapeutics reports second quarter 2018 financial results and business highlights 50

May 11, 2018: Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights 52

Mar 16, 2018: Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights 54

Nov 15, 2017: Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights 55

Aug 15, 2017: Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights 56

May 16, 2017: Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights 58

Mar 31, 2017: Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights 60

Corporate Communications 62

Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 62

May 14, 2018: Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors 63

Apr 02, 2018: Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer 64

Jul 25, 2017: Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer 65

Legal and Regulatory 66

Feb 23, 2017: Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit 66

Government and Public Interest 67

Oct 16, 2017: Abeona Announces USD 13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies 67

Product News 68

12/20/2017: Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB 68

Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 69

05/17/2018: Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting 70

05/12/2017: Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT 71

05/09/2017: Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA 72

05/08/2017: Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting 73

05/02/2017: Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference 74

04/25/2017: Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting 76

02/17/2017: Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium 2017 78

02/07/2018: Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial 80

02/07/2017: Abeona Therapeutics Presents Data on ABO-102 at the 13th Annual WORLDSymposium 2017 82

02/07/2017: Abeona Therapeutics Presents Data on ABO-201 at the 13th Annual WORLDSymposium 2017 83

02/01/2017: Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A 84

Product Approvals 85

May 30, 2017: Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa 85

May 25, 2017: Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa 87

Mar 08, 2017: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa 88

Jan 19, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B 89

Jan 03, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease 90

Clinical Trials 91

Jan 29, 2018: Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa 91

Aug 29, 2017: Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa 92

Aug 17, 2017: Abeona Therapeutics Provides Update on EB-101 at R&D Day on October 11, 2017 93

Aug 16, 2017: Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A 94

Jul 18, 2017: Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa 95

Appendix 96

Methodology 96

About GlobalData 96

Contact Us 96

Disclaimer 96


List Of Figure

List of Figures

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abeona Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Abeona Therapeutics Raises USD3.6 Million in Venture Financing 15

Abeona Therapeutics Raises USD 0.75 Million In Seed Financing 16

Abeona Therapeutics Partners with EB Research Partnership and EB Medical Research Foundation 17

Abeona Therapeutics Enters into Partnership Agreement with University of Nebraska Medical Center 18

Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 19

Abeona Therapeutics Enters into Licensing Agreement with University of North Carolina at Chapel Hill 20

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 21

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 22

PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 23

PlasmaTech Biopharma Enters into Licensing Agreement with UNeMed 24

Access Pharma Enters into Licensing Agreement with Plasma Technologies 25

PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 26

Access Pharma Enters into Licensing Agreement with Norgine for MuGard 27

Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 28

Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 29

Abeona Therapeutics Plans to Raise USD500 Million in Public Offering of Securities 30

Abeona Therapeutics Raises USD92 Million in Public Offering of Shares 31

Abeona Therapeutics Raises USD44 Million in Public Offering of Shares 33

Abeona Therapeutics Raises USD42 Million in Public Offering of Shares 35

Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 37

Abeona Therapeutics Raises USD4.6 Million in Private Placement of Shares up on Exercise of Warrants 38

PlasmaTech Biopharma Raises USD10 Million in Private Placement of Shares 39

PlasmaTech Biopharma Raises USD7 Million in Private Placement of Shares 40

PlasmaTech Biopharma Raises USD14 Million in Public Offering of Shares and Warrants 41

Access Pharma Completes Private Placement Of Units For USD 4.7 Million 43

Access Pharma Files Registration Statement For Public Offering Of Units 44

PlasmaTech Biopharma Acquires Abeona Therapeutics 45

Abeona Therapeutics Inc, Key Competitors 46

Abeona Therapeutics Inc, Key Employees 47

Abeona Therapeutics Inc, Subsidiaries 48

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Abeona Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. The company's lead programs include ABO-101 and ABO-102 adeno-associated virus. Abeona is also develops EB-101 for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 for rare blood diseases. The company has partnership with for the commercialization of its products in the US, European Union, Switzerland, Norway, Iceland, Lichtenstein, Australia, New Zealand, China and South Korea. Abeona is headquartered in Dallas, Texas, the US.

Abeona Therapeutics Inc (ABEO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 15

Venture Financing 15

Abeona Therapeutics Raises USD3.6 Million in Venture Financing 15

Abeona Therapeutics Raises USD 0.75 Million In Seed Financing 16

Partnerships 17

Abeona Therapeutics Partners with EB Research Partnership and EB Medical Research Foundation 17

Abeona Therapeutics Enters into Partnership Agreement with University of Nebraska Medical Center 18

Licensing Agreements 19

Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 19

Abeona Therapeutics Enters into Licensing Agreement with University of North Carolina at Chapel Hill 20

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 21

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 22

PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 23

PlasmaTech Biopharma Enters into Licensing Agreement with UNeMed 24

Access Pharma Enters into Licensing Agreement with Plasma Technologies 25

PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 26

Access Pharma Enters into Licensing Agreement with Norgine for MuGard 27

Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 28

Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 29

Equity Offering 30

Abeona Therapeutics Plans to Raise USD500 Million in Public Offering of Securities 30

Abeona Therapeutics Raises USD92 Million in Public Offering of Shares 31

Abeona Therapeutics Raises USD44 Million in Public Offering of Shares 33

Abeona Therapeutics Raises USD42 Million in Public Offering of Shares 35

Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 37

Abeona Therapeutics Raises USD4.6 Million in Private Placement of Shares up on Exercise of Warrants 38

PlasmaTech Biopharma Raises USD10 Million in Private Placement of Shares 39

PlasmaTech Biopharma Raises USD7 Million in Private Placement of Shares 40

PlasmaTech Biopharma Raises USD14 Million in Public Offering of Shares and Warrants 41

Access Pharma Completes Private Placement Of Units For USD 4.7 Million 43

Access Pharma Files Registration Statement For Public Offering Of Units 44

Acquisition 45

PlasmaTech Biopharma Acquires Abeona Therapeutics 45

Abeona Therapeutics Inc-Key Competitors 46

Abeona Therapeutics Inc-Key Employees 47

Abeona Therapeutics Inc-Locations And Subsidiaries 48

Head Office 48

Other Locations & Subsidiaries 48

Recent Developments 49

Strategy And Business Planning 49

Oct 04, 2017: Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio 49

Financial Announcements 50

Aug 09, 2018: Abeona Therapeutics reports second quarter 2018 financial results and business highlights 50

May 11, 2018: Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights 52

Mar 16, 2018: Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights 54

Nov 15, 2017: Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights 55

Aug 15, 2017: Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights 56

May 16, 2017: Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights 58

Mar 31, 2017: Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights 60

Corporate Communications 62

Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 62

May 14, 2018: Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors 63

Apr 02, 2018: Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer 64

Jul 25, 2017: Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer 65

Legal and Regulatory 66

Feb 23, 2017: Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit 66

Government and Public Interest 67

Oct 16, 2017: Abeona Announces USD 13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies 67

Product News 68

12/20/2017: Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB 68

Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 69

05/17/2018: Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting 70

05/12/2017: Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT 71

05/09/2017: Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA 72

05/08/2017: Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting 73

05/02/2017: Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference 74

04/25/2017: Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting 76

02/17/2017: Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium 2017 78

02/07/2018: Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial 80

02/07/2017: Abeona Therapeutics Presents Data on ABO-102 at the 13th Annual WORLDSymposium 2017 82

02/07/2017: Abeona Therapeutics Presents Data on ABO-201 at the 13th Annual WORLDSymposium 2017 83

02/01/2017: Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A 84

Product Approvals 85

May 30, 2017: Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa 85

May 25, 2017: Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa 87

Mar 08, 2017: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa 88

Jan 19, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B 89

Jan 03, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease 90

Clinical Trials 91

Jan 29, 2018: Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa 91

Aug 29, 2017: Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa 92

Aug 17, 2017: Abeona Therapeutics Provides Update on EB-101 at R&D Day on October 11, 2017 93

Aug 16, 2017: Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A 94

Jul 18, 2017: Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa 95

Appendix 96

Methodology 96

About GlobalData 96

Contact Us 96

Disclaimer 96


List Of Figure

List of Figures

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abeona Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12

Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Abeona Therapeutics Raises USD3.6 Million in Venture Financing 15

Abeona Therapeutics Raises USD 0.75 Million In Seed Financing 16

Abeona Therapeutics Partners with EB Research Partnership and EB Medical Research Foundation 17

Abeona Therapeutics Enters into Partnership Agreement with University of Nebraska Medical Center 18

Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 19

Abeona Therapeutics Enters into Licensing Agreement with University of North Carolina at Chapel Hill 20

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 21

Abeona Therapeutics Enters into Licensing Agreement with Stanford University 22

PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 23

PlasmaTech Biopharma Enters into Licensing Agreement with UNeMed 24

Access Pharma Enters into Licensing Agreement with Plasma Technologies 25

PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 26

Access Pharma Enters into Licensing Agreement with Norgine for MuGard 27

Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 28

Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 29

Abeona Therapeutics Plans to Raise USD500 Million in Public Offering of Securities 30

Abeona Therapeutics Raises USD92 Million in Public Offering of Shares 31

Abeona Therapeutics Raises USD44 Million in Public Offering of Shares 33

Abeona Therapeutics Raises USD42 Million in Public Offering of Shares 35

Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 37

Abeona Therapeutics Raises USD4.6 Million in Private Placement of Shares up on Exercise of Warrants 38

PlasmaTech Biopharma Raises USD10 Million in Private Placement of Shares 39

PlasmaTech Biopharma Raises USD7 Million in Private Placement of Shares 40

PlasmaTech Biopharma Raises USD14 Million in Public Offering of Shares and Warrants 41

Access Pharma Completes Private Placement Of Units For USD 4.7 Million 43

Access Pharma Files Registration Statement For Public Offering Of Units 44

PlasmaTech Biopharma Acquires Abeona Therapeutics 45

Abeona Therapeutics Inc, Key Competitors 46

Abeona Therapeutics Inc, Key Employees 47

Abeona Therapeutics Inc, Subsidiaries 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Abeona Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.